UBS downgrades Galderma stock rating to neutral citing limited upside

UBS downgraded Galderma Group AG (SWX:GALD) to Neutral from Buy, reducing its price target to CHF120.00 from CHF128.00, citing "more limited upside" after the stock's recent strong performance. While UBS's Q2 2025 US Aesthetics Survey revealed robust neuromodulator trends, it indicated a weaker outlook for fillers and biostimulators amid increased promotional activity. Despite this, UBS raised near-term sales estimates for Galderma's Nemluvio product due to its strong launch, maintaining its $3 billion peak sales forecast.

Analysis

UBS has recalibrated its stance on Galderma Group AG (GALD), downgrading the stock to Neutral from Buy and lowering its price target to CHF120 from CHF128. This revision is principally a valuation call, with the bank citing "more limited upside" potential after a period of strong share price performance, rather than a deterioration in the company's fundamental outlook. The analysis presents a bifurcated view of Galderma's business segments based on a Q2 2025 US Aesthetics Survey. While the survey indicates continued strength for neuromodulators, it signals a weaker outlook for fillers and biostimulators, a trend exacerbated by increased promotional activity which could imply future margin pressure. Conversely, the therapeutics division is showing strength, with the launch of the Nemluvio product described as continuing "strongly." This has prompted UBS to raise its near-term sales estimates for the treatment, although it is maintaining its long-term $3 billion peak sales forecast, suggesting the product's ultimate potential is currently seen as unchanged.

Key Decisions for Investors

• Given that the downgrade is primarily based on valuation following a strong run, investors holding GALD should weigh the now more limited upside against the new CHF120 price target when considering position sizing.
• Potential investors should balance the positive momentum from the strong Nemluvio product launch against the emerging headwinds in the aesthetics division, specifically the weaker outlook for fillers and increased promotional activity.
• Monitor future earnings reports for commentary on margins within the aesthetics segment and for the sales trajectory of Nemluvio to gauge if it can continue to outperform near-term estimates.